An international Delphi consensus regarding best practice recommendations for hyperkalaemia across the cardiorenal spectrum

Renin–angiotensin–aldosterone system inhibitors (RAASi) are guideline‐recommended therapy for individuals with cardiorenal disease. They are associated with increased risk of hyperkalaemia, a common and life‐threatening disorder for this population. RAASi‐induced hyperkalaemia often leads to dose reduction or discontinuation, reducing cardiorenal protection. Guideline recommendations differ between specialties for the clinical management of hyperkalaemia. Using a modified Delphi method, we developed consensus recommendations for optimal management of hyperkalaemia in adults with cardiorenal disease.

[1]  G. Sinagra,et al.  [ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: what's new?] , 2022, Giornale italiano di cardiologia.

[2]  David W. Johnson,et al.  Dietary Potassium Intake and All-Cause Mortality in Adults Treated with Hemodialysis , 2021, Clinical journal of the American Society of Nephrology : CJASN.

[3]  K. Khunti,et al.  Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years , 2021, EClinicalMedicine.

[4]  L. Anderson,et al.  Management and outcomes of heart failure patients with CKD: experience from an inter‐disciplinary clinic , 2020, ESC heart failure.

[5]  K. Kalantar-Zadeh,et al.  Longer predialysis ACEi/ARB utilization is associated with reduced postdialysis mortality. , 2020, The American journal of medicine.

[6]  G. Filippatos,et al.  Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC‐HFA‐EORP Heart Failure Long‐Term Registry , 2020, European journal of heart failure.

[7]  R. Sankaranarayanan,et al.  Cardio-nephrology MDT meetings play an important role in the management of cardiorenal syndrome. , 2020, The British journal of cardiology.

[8]  A. Wang,et al.  Optimally managing hyperkalemia in patients with cardiorenal syndrome. , 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  B. Williams,et al.  Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial , 2019, The Lancet.

[10]  I. Piña,et al.  Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. , 2019, Kidney international.

[11]  Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND) , 2019, Case Medical Research.

[12]  G. Rosano,et al.  Hyperkalemia and Renin–Angiotensin–Aldosterone System Inhibitors Dose Therapy in Heart Failure With Reduced Ejection Fraction , 2019, Cardiac failure review.

[13]  D. Pennell,et al.  Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial , 2019, The Lancet.

[14]  P. Ponikowski,et al.  Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology , 2018, European heart journal. Cardiovascular pharmacotherapy.

[15]  L. Lund,et al.  Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists , 2018, European journal of heart failure.

[16]  G. Filippatos,et al.  Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease , 2018, ESC heart failure.

[17]  R. McKelvie,et al.  2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. , 2017, The Canadian journal of cardiology.

[18]  Akshay S. Desai,et al.  Initiation, Continuation, or Withdrawal of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction , 2017, Journal of the American Heart Association.

[19]  G. Bakris,et al.  Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. , 2016, Kidney international.

[20]  S. Brunelli,et al.  Association between Serum Potassium and Outcomes in Patients with Reduced Kidney Function. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[21]  N. Oestreicher,et al.  Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. , 2015, The American journal of managed care.

[22]  Josh Batterink,et al.  Effectiveness of Sodium Polystyrene Sulfonate for Short-Term Treatment of Hyperkalemia. , 2015, The Canadian journal of hospital pharmacy.

[23]  P. Lavin,et al.  Sodium zirconium cyclosilicate in hyperkalemia. , 2015, The New England journal of medicine.

[24]  David C. Wheeler,et al.  Notice , 2012, Kidney International Supplements.